About NuGEN
NuGEN is a Healthcare company based in San Carlos (United States) founded in 2000, and was acquired by Tecan in August 2018. Amplification products for genomic analysis are developed and supplied. NuGEN has raised $53.53 million across 9 funding rounds from investors including Tecan, Alloy Ventures and Sutter Hill Ventures. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its competitors include Neogen, RareCyte and Paragon Genomics; 3 of its 3 listed competitors have raised funding.
Company details
NuGEN provides amplification products for genomic analysis. It has three platform technologies used to develop amplification kits for next-gen systems, microarrays, and PCR: Single Primer Enrichment Technology (SPET) enables targeted resequencing of genomic DNA Insert Dependent Adaptor Cleavage (InDA-C) removes certain targeted transcripts from RNA-Seq libraries without impacting the rest; Single Primer Isothermal Amplification is used to amplify DNA isothermally for whole genome and whole transcriptome sequencing.
Funding Insights of NuGEN
NuGEN has successfully raised a total of $53.53M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $6.18 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $53.53M
- Total Rounds 9
- Last Round Series D — $6.18M
- First Round $2M
(Nov 2000)
- Investors Count 5
All 9 funding rounds of NuGEN with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2014 | $6.18M | Series D | – | – | – |
| Aug 2011 | $3.5M | Series C | – | – | – |
| Aug 2011 | $3.5M | Series C | – | – | – |
| Mar 2010 | $1.5M | Series C | – | – | – |
| Mar 2006 | $7.75M | Series C | – | – | |
| Aug 2003 | $7.5M | Series C | – | – | |
| Dec 2001 | $10.8M | Series B | – | – | |
| Dec 2001 | $10.8M | Series B | – | – | |
| Nov 2000 | $2M | Series A | – | – | – |
6 investors in total: 6 institutional.
Investors in NuGEN
NuGEN has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Tecan, Alloy Ventures and Sutter Hill Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage venture capital firm investing in the US | alloyventures.com | Palo Alto, United States | ||
VC firm investing in the US | shv.com | Palo Alto, United States | ||
| radiusventures.com | ||||
Angel investing in high-tech and life science startups since 1994. | bandangels.com | |||
| pequotcap.com | ||||
Automated laboratory instruments, robotics, and diagnostic solutions are provided. | 1980 | tecan.com | Mannedorf, Switzerland |
Investor details for NuGEN
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NuGEN
4 dated milestones of NuGEN across 18 years, from founding to its latest funding, stage changes and deals.
- Founded NuGEN is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series D, of $6.2M.
- Exit Acquired by Tecan.
Competitors of NuGEN
NuGEN has 3 listed competitors in our database, 3 of them funded. They include Neogen, RareCyte and Paragon Genomics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| paragongenomics.com | 2015 | San Francisco, United States | $8M | 26 | Provider of technologies and solutions genomic research and precision medicine |
Detailed competitors of NuGEN
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NuGEN
Websites that share an audience with NuGEN (nugen.com).
Websites whose visitors overlap most with NuGEN. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| illumina.com | 100% | 672.7K | #61,793 | View details | |
bionexus.net | bionexus.net | 98% | #11,390,327 | – | |
| neb.com | 96% | 749.5K | #69,042 | View details | |
| scienceexchange.com | 92% | 2.9K | #4,037,937 | View details | |
| nanostring.com | 89% | 94.7K | #498,957 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for NuGEN
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as NuGEN (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nugen
Complete news archive for NuGEN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NuGEN
NuGEN was founded in 2000.
NuGEN is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.
NuGEN is a funded company, having raised a total of $53.53M across 9 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Nov 2000.
NuGEN provides amplification products for genomic analysis. It has three platform technologies used to develop amplification kits for next-gen systems, microarrays, and PCR: Single Primer Enrichment Technology (SPET) enables targeted resequencing of genomic DNA Insert Dependent Adaptor Cleavage (InDA-C) removes certain targeted transcripts from RNA-Seq libraries without impacting the rest; Single Primer Isothermal Amplification is used to amplify DNA isothermally for whole genome and whole transcriptome sequencing.
NuGEN's top competitors include Neogen, Paragon Genomics and RareCyte.
NuGEN has 6 investors. Key investors include Tecan, Alloy Ventures, Sutter Hill Ventures, Radius Ventures, and Band of Angels.
Yes. NuGEN was acquired by Tecan in August 2018.